HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 452-463

  Cartron, Pierre François ^a,b   Blanquart, Christophe ^a,b   Hervouet, Eric ^a,b   Gregoire, Marc ^a,b   Vallette, François M ^a,b,c  

^a Groupe Cytokines et Récepteurs   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Institut de Cancerologie de l'Ouest   (France)

Author keywords

Dnmt; Epigenetic; Glioma; HDAC; Mesothelioma; NY ESO1

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; EARLY GROWTH RESPONSE FACTOR 1; HISTONE; HISTONE DEACETYLASE 1; MULTIPROTEIN COMPLEX; NUCLEAR RECEPTOR COREPRESSOR; TRANSCRIPTION FACTOR SIN3A;

ARTICLE; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; GENE CONTROL; HISTONE METHYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION;

EID: 84878111934     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.11.004     Document Type: Article

References (26)

1. Bostick M., Kim J., Estève P., Clark A., Pradhan S., Jacobsen S. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007, 27:2187-2197.
2. Cronwright G., Le Blanc K., Götherström C., Darcy P., Ehnman M., Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005, 65:2207-2215.
3. Dovey O., Foster C., Cowley S. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8242-8247.
4. Ecke I., Petry F., Rosenberger A., Tauber S., Mönkemeyer S., Hess I., Dullin C., Kimmina S., Pirngruber J., Johnsen S., Uhmann A., Nitzki F., Wojnowski L., Schulz-Schaeffer W., Witt O., Hahn H. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009, 69:887-895.
5. Greer E., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13:343-357.
6. Guillot F., Boutin B., Blanquart C., Fonteneau J., Robard M., Grégoire M., Pouliquen D. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine 2011, 29:5534-5543.
7. Hegi M., Diserens A., Gorlia T., Hamou M., de Tribolet N., Weller M., Kros J., Hainfellner J., Mason W., Mariani L., Bromberg J., Hau P., Mirimanoff R., Cairncross J., Janzer R., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:991-1003.
8. Hervouet E., Vallette F., Cartron P. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2010, 1. 10.1038/cddis.2009.1037.
9. Hervouet E., Vallette F.M., Cartron P.F. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 2009, 4.
10. Hervouet E., Vallette F.M., Cartron P.F. Dnmt1/transcription factor interactions: an alternative mechanism of DNA methylation inheritance. Genes & Cancer 2010, 1:434-443.
11. James S., Link P., Karpf A. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006, 25:6975-6985.
12. Kang Y., Hong J., Chen G., Nguyen D., Schrump D. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007, 26:4394-4403.
13. Karpf A. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006, 1:116-120.
14. Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., Padieu M., Pouliquen D., Fonteneau J., Grégoire M. 5-aza-2'-deoxycytidine/valproate combination induces CTL response against mesothelioma. Eur. Respir. J. 2011, 5:1105-1116.
15. Maio M., Coral S., Fratta E., Altomonte M., Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene 2003, 22:6484-6488.
16. Métivier R., Gallais R., Tiffoche C., Le Péron C., Jurkowska R., Carmouche R., Ibberson D., Barath P., Demay F., Reid G., Benes V., Jeltsch A., Gannon F., Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452:45-50.
17. Miller K., Tjeertes J., Coates J., Legube G., Polo S., Britton S., Jackson S. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA non homologous end-joining. Nat. Struct. Mol. Biol. 2010, 17:1144-1151.
18. Mund C., Brueckner B., Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2005, 1:7-13.
19. Natsume A., Kondo Y., Ito M., Motomura K., Wakabayashi T., Yoshida J. Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci. 2010, [Epub ahead of print].
20. Oi S., Natsume A., Ito M., Kondo Y., Shimato S., Maeda Y., Saito K., Wakabayashi T. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. J. Neurooncol. 2009, 92:15-22.
21. Okada H., Kohanbash G., Zhu X., Kastenhuber E., Hoji A., Ueda R., Fujita M. Immunotherapeutic approaches for glioma. Crit. Rev. Immunol. 2009, 29:1-42.
22. Sahin U., Koslowski M., Türeci O., Eberle T., Zwick C., Romeike B., Moringlane J., Schwechheimer K., Feiden W., Pfreundschuh M. Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 2000, 6:3916-3922.
23. Sharif J., Muto M., Takebayashi S., Suetake I., Iwamatsu A., Endo T., Shinga J., Mizutani-Koseki Y., Toyoda T., Okamura K., Tajima S., Mitsuya K., Okano M., Koseki H. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007, 450:908-912.
24. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P., Libener R., Colizzi F., Vianale G., Martini F., Tognon M., Jungbluth A., Cebon J., Maraskovsky E., Mutti L., Maio M. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bio immunotherapeutic implications. Br. J. Cancer 2002, 86:979-982.
25. Sigalotti L., Coral S., Fratta E., Lamaj E., Danielli R., Di Giacomo A., Altomonte M., Maio M. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 2005, 32:473-478.
26. Vaissière T., Sawan C., Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 2008, 659:40-48.